免疫衰老与皮肤恶性黑素瘤相关性的研究进展

doi:10.3969/j.issn.1004-616x.2025.04.004

癌变·畸变·突变 ›› 2025, Vol. 37 ›› Issue (4): 274-276.doi: 10.3969/j.issn.1004-616x.2025.04.004

• 专题研究 • 上一篇

免疫衰老与皮肤恶性黑素瘤相关性的研究进展

李峰, 晋红中

中国医学科学院北京协和医学院北京协和医院皮肤科, 疑难重症及罕见病国家重点实验室, 国家皮肤与免疫疾病临床医学研究中心, 北京 100730

收稿日期:2025-04-23 修回日期:2025-05-29 发布日期:2025-08-05
通讯作者: 晋红中
作者简介:李峰，E-mail：lifeng@pumch.cams.cn。
基金资助:
北京市临床重点专科项目；国家临床重点专科建设项目

Research progress on the correlation between immunosenescence and cutaneous malignant melanoma

LI Feng, JIN Hongzhong

Received:2025-04-23 Revised:2025-05-29 Published:2025-08-05

摘要/Abstract

摘要： 免疫衰老是指随着年龄的增长，伴随免疫细胞功能衰退、炎症反应增强、免疫系统功能下降的现象，与多种疾病的发病机制有关。皮肤恶性黑素瘤是一种具有高度侵袭性的皮肤肿瘤，其发病机制与机体免疫状态存在相关性。免疫衰老可能通过促进免疫逃逸、影响肿瘤微环境等途径对黑素瘤的发生发展产生重要影响，也可能影响黑素瘤的治疗反应。深入理解免疫衰老在皮肤恶性黑素瘤发病中的作用，有助于揭示该病的发病机制，并为其临床治疗提供新的视角。因此，本文主要对免疫衰老在皮肤恶性黑素瘤的发生发展及免疫治疗反应等方面的研究进展进行综述。

关键词: 免疫衰老, 皮肤恶性黑素瘤, 肿瘤微环境, 免疫逃逸, 治疗反应

中图分类号:

R730.51

李峰, 晋红中. 免疫衰老与皮肤恶性黑素瘤相关性的研究进展[J]. 癌变·畸变·突变, 2025, 37(4): 274-276.

LI Feng, JIN Hongzhong. Research progress on the correlation between immunosenescence and cutaneous malignant melanoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 274-276.

参考文献

[1] JOSHI K, ATWAL D, RAVILLA R, et al. Immunotherapy outcomes in advanced melanoma in relation to age[J]. Perm J, 2020, 24: 19.093.
[2] WANG X Y, GUO S, ZHOU H X, et al. Pan-cancer transcriptomic analysis identified six classes of immunosenescence genes revealed molecular links between aging, immune system and cancer[J]. Genes Immun, 2023, 24(2): 81-91.
[3] ZHU L Y, ZHANG L Y, QI J H, et al. Machine learning-derived immunosenescence index for predicting outcome and drug sensitivity in patients with skin cutaneous melanoma[J]. Genes Immun, 2024, 25(3): 219-231.
[4] HONG H, WANG Q, LI J, et al. Aging, cancer and immunity[J]. J Cancer, 2019, 10(13): 3021-3027.
[5] KAKUDA T, SUZUKI J, MATSUOKA Y, et al. Senescent CD8+ T cells acquire NK cell-like innate functions to promote antitumor immunity[J]. Cancer Sci, 2023, 114(7): 2810-2820.
[6] FORLIN R, JAMES A, BRODIN P. Making human immune systems more interpretable through systems immunology[J]. Trends Immunol, 2023, 44(8): 577-584.
[7] SIBAII H, EL-ZAYAT S R, KHALIL M. When wrinkles appear on the immune system can it be reversed-[J]. Eur Cytokine Netw, 2020, 31(1): 1-17.
[8] APRILIA A, HANDONO K, SUJUTI H, et al. sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence[J]. Immun Ageing, 2024, 21: 9.
[9] ANDEWEG S P, KE-MIR C, DUTILH B E. Quantifying the impact of human leukocyte antigen on the human gut microbiota[J]. mSphere, 2021, 6(4): e0047621.
[10] FUESS L E, DEN HAAN S, LING F, et al. Immune gene expression covaries with gut microbiome composition in stickleback[J]. mBio, 2021, 12(3): e00145-21.
[11] LóPEZ RIQUELME I, MARTíNEZ GARCíA S, SERRANO ORDóNEZ A, et al. Germline mutations predisposing to melanoma and associated malignancies and syndromes: a narrative review[J]. Int J Dermatol, 2025, 64(6): 1027-1041.
[12] VRANIC S, SERMAN N, GLIBO M, et al. Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: a concise review[J]. Bosn J Basic Med Sci, 2022: 673-682.
[13] LIYANAGE U E, MACGREGOR S, BISHOP D T, et al. Multi-trait genetic analysis identifies autoimmune loci associated with cutaneous melanoma[J]. J Invest Dermatol, 2022, 142(6): 1607-1616.
[14] YAMAUCHI T, SHANGRAW S, ZHAI Z, et al. Alcohol as a Non-UV Social-Environmental Risk Factor for Melanoma[J]. Cancers (Basel). 2022；14(20): 5010.
[15] PODLIPNIK S, POTRONY M, PUIG S. Genetic markers for characterization and prediction of prognosis of melanoma subtypes: a 2021 update[J]. Ital J Dermatol Venerol, 2021, 156(3): 322-330.
[16] KUMAR P, BRAZEL D, DEROGATIS J, et al. The cure from within- a review of the microbiome and diet in melanoma[J]. Cancer Metastasis Rev, 2022, 41(2): 261-280.
[17] FRUNTEALAT- R F, MARIUS M, BOBOC I K S, et al. Mechanisms of altered immune response in skin melanoma[J]. Curr Health Sci J, 2023, 49(3): 297-311.
[18] DU Z M, FENG Y Y, ZHANG H, et al. Melanoma-derived small extracellular vesicles remodel the systemic onco-immunity via disrupting hematopoietic stem cell proliferation and differentiation[J]. Cancer Lett, 2022, 545: 215841.
[19] HUANG L Y, ZHANG M F, BAI D, et al. Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization[J]. Front Immunol, 2024, 15: 1465006.
[20] DENG Y, GAO H Y, WU Q H. T-2 toxin induces immunosenescence in RAW264.7 macrophages by activating the HIF-1α/cGAS-STING pathway[J]. J Agric Food Chem, 2024, 72(43): 24046-24057.
[21] SANTOS T D, HICKS W L Jr, MAGNER W J, et al. Metabolic and aging influence on anticancer immunity in oral cancer[J]. J Dent Res, 2024, 103(10): 953-961.
[22] CONG F Y, ZHANG Y, XU J, et al. The effect of abnormal lipid metabolism on immunosenescence of the colonic Lamina propria in mice of different ages[J]. Immunol Lett, 2024, 270: 106940.
[23] LIU Z Q, LIANG Q M, REN Y Q, et al. Immunosenescence: molecular mechanisms and diseases[J]. Sig Transduct Target Ther, 2023, 8: 200.
[24] LIU Z Q, ZUO L L, ZHOU Z K, et al. Targeting immunosenescence for improved tumor immunotherapy[J]. Med Comm (2020), 2024, 5(11): e777.
[25] SUN H, HONG Q, LI C, et al. Immunosenescence in sepsis: molecular mechanisms and potential therapeutic targets[J]. Aging Dis. 2025 Mar 14. doi: 10.14336/AD.2025.0039. Online ahead of print.
[26] XU B, LUO Z, NIU X, et al. Fungi, immunosenescence and cancer[J]. Semin Cancer Biol, 2025, 109: 67-82.
[27] LIU Y R, LI D, YU X Q, et al. Identification of a novel immunosenescence-related genes and integrative analyses in patients with psoriasis[J]. Hum Immunol, 2025, 86(1): 111218.
[28] ZIOGAS D C, THEOCHAROPOULOS C, ARAVANTINOU K, et al. Clinical benefit of immune checkpoint inhibitors in elderly cancer patients: Current evidence from immunosenescence pathophysiology to clinical trial results[J]. Crit Rev Oncol Hematol, 2025, 208: 104635.

免疫衰老与皮肤恶性黑素瘤相关性的研究进展

Research progress on the correlation between immunosenescence and cutaneous malignant melanoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

本文评价

[1]	刘壮壮, 肖汀. 肿瘤微环境中衰老细胞的可塑性及靶向策略[J]. 癌变·畸变·突变, 2025, 37(4): 268-270,276.
[2]	葛增威, 肖汀. 衰老巨噬细胞在肿瘤发生发展中的作用及其干预策略[J]. 癌变·畸变·突变, 2025, 37(4): 271-273.
[3]	谢佩佩, 张颀, 张小利, 万朵, 张文, 程书钧, 张开泰. 原发性肺腺癌患者外周血端粒酶逆转录酶阳性白细胞检测方法的建立[J]. 癌变·畸变·突变, 2024, 36(6): 431-437,443.
[4]	张开泰. 衰老与恶性肿瘤——被忽视的免疫衰老[J]. 癌变·畸变·突变, 2024, 36(3): 169-171.
[5]	康文义, 汪献旺, 张为家. CD73在肿瘤免疫逃逸中作用的研究进展[J]. 癌变·畸变·突变, 2024, 36(3): 244-247.
[6]	梁敏, 肖艳红, 刘艳灵, 王伟岩, 刘芹芹, 滕清良. 调节性T细胞在抗肿瘤免疫及治疗中的研究进展[J]. 癌变·畸变·突变, 2022, 34(6): 481-484.
[7]	马亚南, 吴楠, 金焰. 肿瘤微环境与卵巢癌化疗耐药机制的研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 393-395,400.
[8]	徐苗, 张天一, 田菲菲. PD-1/PD-L1信号通路抑制剂在宫颈癌治疗中的研究进展[J]. 癌变·畸变·突变, 2019, 31(5): 417-420.
[9]	王明慧，冯林，张开泰，肖汀*. 协同刺激分子B7-H4与恶性肿瘤关系的研究进展[J]. 癌变·畸变·突变, 2014, 26(5): 392-395.
[10]	石嘉俪(综述), 周佳青*(审校). 甲状腺癌侵袭性相关的分子生物学研究进展[J]. , 2011, 23(4): 319-321.
[11]	郜明/ 吴家明(综述)/ 陆　茵, (审校). 肿瘤微环境与肿瘤的恶变[J]. 癌变·畸变·突变, 2008, 20(5): 412-414.